GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nectar Lifesciences Ltd (LUX:NECLF) » Definitions » Total Equity

Nectar Lifesciences (LUX:NECLF) Total Equity : $128.8 Mil (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Nectar Lifesciences Total Equity?

Nectar Lifesciences's total equity for the quarter that ended in Mar. 2024 was $128.8 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Nectar Lifesciences Total Equity Historical Data

The historical data trend for Nectar Lifesciences's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nectar Lifesciences Total Equity Chart

Nectar Lifesciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 152.40 145.84 142.79 129.41 128.79

Nectar Lifesciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 129.41 - 128.50 - 128.79

Nectar Lifesciences Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Nectar Lifesciences's Total Equity for the fiscal year that ended in Mar. 2024 is calculated as

Total Equity=Total Assets(Q: Mar. 2024 )-Total Liabilities(Q: Mar. 2024 )
=263.915-135.123
=128.8

Nectar Lifesciences's Total Equity for the quarter that ended in Mar. 2024 is calculated as

Total Equity=Total Assets(Q: Mar. 2024 )-Total Liabilities(Q: Mar. 2024 )
=263.915-135.123
=128.8

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nectar Lifesciences Total Equity Related Terms

Thank you for viewing the detailed overview of Nectar Lifesciences's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Nectar Lifesciences (LUX:NECLF) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nectar Lifesciences Ltd (LUX:NECLF) » Definitions » Total Equity
Comparable Companies
BOM:532305 BOM:506414 BOM:524075 BOM:541400 NSE:SAKAR BOM:540937 BOM:532039 BOM:524500 BOM:539730 BOM:506260 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
NECLIFE:India 532649:India
Address
SCO 38-39, Sector 9d, B-1011/1012, 10th Floor NAURANG HOUSE, Chandigarh, IND, 160009
Website
https://www.neclife.com
Nectar Lifesciences Ltd is an India-based pharmaceutical company. It is engaged in manufacturing specialized pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and finished dosage formulations. It operates in the business segment of Pharmaceuticals Products, The company's product includes cefixime trihydrate, cefdinir, cefprozil, cefoxitin sodium, cefpirome sulphate, and others. Geographically, it derives a majority of its revenue from India.

Nectar Lifesciences (LUX:NECLF) Headlines

No Headlines